1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Micro-Tech (Nanjing) Co., Ltd.

Micro-Tech (Nanjing) Co., Ltd.

688029.SS
Micro-Tech (Nanjing) Co., Ltd.CN flagShanghai Stock Exchange
75.77
CNY
+0.62
- -
14.14BMarket Cap
Micro-Tech (Nanjing) Co., Ltd.
688029.SS
(Shanghai Stock Exchange)

Recent

price

75.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
8.72
2.92
2.07
3.11
4.58
6.59
8.2
7.11
10.43
10.6
12.85
14.69
17.03
15.96
Revenue per Share
- -
- -
- -
1.28
0.42
0.25
-0.27
0.72
1.38
1.9
1.4
1.74
1.77
2.59
2.95
3.05
3.24
Basic EPS, GAAP
- -
- -
- -
-1.36
0.12
-0.33
0.33
0.62
1.03
1.25
0.37
0.04
0.2
1.54
1.83
2.32
-1.61
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.08
0.16
0.03
0.03
0.36
0.25
0.34
0.54
0.56
1.51
1.51
1.52
Dividend per Share
- -
- -
- -
5.6
2.46
0.87
0.5
1.14
2.03
3.73
3.74
4.89
6.41
8.42
9.88
11.46
10.84
Book Value per Share
- -
- -
- -
11.28
3.41
1.55
2.15
2.8
3.53
14.93
13.48
14.79
16.3
18.14
19.49
20.08
19.8
Tangible Book Value per Share
- -
- -
- -
19
69
126
133
140
140
159
187
187
187
188
188
187
187
Basic Weighted Avg Shares
82
108
127
169
203
261
414
641
922
1,307
1,326
1,947
1,980
2,411
2,755
3,184
2,987
Sales/Revenue/Turnover
36.62
31.86
27.01
12.84
17.18
15.25
-3.32
21.6
23.02
24.52
19.88
17.79
14.32
20.1
23.64
20.78
22.55
Operating Margin (%)
1
2
2
5
6
- -
9
12
16
20
26
45
61
69
88
124
- -
Depreciation Expense
24
32
32
25
29
31
-36
101
193
304
261
325
331
486
553
570
606
Net Income, GAAP
15.01
14.57
14.85
17.48
19.04
17.02
- -
14.68
13.11
12.16
11.58
12.72
9.52
12.43
13.9
15.71
14.74
Effective Tax Rate (%)
29.65
29.77
24.93
14.72
14.45
12.01
-8.8
15.79
20.9
23.22
19.66
16.68
16.7
20.15
20.08
17.91
20.29
Profit Margin (%)
54
82
100
172
164
93
181
215
314
2,077
2,069
2,205
2,425
2,641
2,514
2,638
2,538
Working Capital
1
24
24
- -
- -
- -
35
56
15
- -
15
8
5
25
25
34
35
LT Debt
64
86
117
233
262
300
359
466
620
2,528
2,664
2,990
3,274
3,670
3,899
4,342
4,197
Total Equity
45.95
32.13
22.06
9.36
11.29
10.74
- -
23.59
28.57
17.28
8.92
10.59
8.12
12.06
14.54
13
13.95
Return on Invested Capital (%)
53.8
41.42
29.08
20.85
20.91
16.32
- -
41.84
52.39
54.98
35.91
36.7
29.53
32.67
29.75
24.65
28.46
Return on Capital (%)
53.07
50.37
36.42
23.71
20.93
22.32
-41.45
89.56
86.92
69.07
40.3
40.3
31.34
35
32.24
28.56
32.49
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
14
24
81
LT Borrowings
- -
- -
- -
LT Finance Leases
25
33
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
188
188
188
Market Capitalization
12,759
12,332
12,641

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,321
3,223
3,335
Cash, Cash Equivalents & STI
1,887
1,861
2,018
Accounts Receivable, Net
434
523
555
Inventories
537
616
628
Total Current Liabilities
806
707
798
Payables & Accruals
- -
- -
- -
ST Debt
14
24
81
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
44.68%
10.29%
11.36%
Free Cash Flow
92.54%
199.14%
26.1%
Net Income, GAAP
-36.98%
18.05%
3.09%
Sales/Revenue/Turnover
30.08%
20.02%
15.55%
Total Cash Common Dividend
155.02%
54.36%
-0.4%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
620
714
679
743
2,755
2025
699
866
803
- -
3,184
2026
854
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
- -
- -
- -
2.95
2025
0.86
- -
- -
- -
3.05
2026
0.78
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.51
2025
0.01
- -
- -
- -
1.51
2026
- -
- -
- -
- -
- -
Similar Companies
Sartorius Stedim Biotech S.A. (DIM.PA)
Kawamoto Corporation (3604.T)
Baumer S.A. (BALM4.SA)
Sanara MedTech Inc. (SMTI)
Cambridge Nutritional Sciences plc (CNSL.L)
iRay Technology Company Limited (688301.SS)
Business
Micro-Tech (Nanjing) Co., Ltd. engages principally in the research, development, manufacturing and sales of minimally invasive medical devices, with a focus on endoscopic diagnosis and treatment instruments, tumor ablation products and endoscopic imaging systems. The company offers three core product platforms: endoscopic diagnostic instruments and consumables including biopsy forceps, hemostasis and closure devices, endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) tools, dilation balloons, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography (EUS) and endobronchial ultrasound (EBUS) products; microwave ablation equipment and consumables such as microwave ablation instruments and needles; and disposable endoscopes including biliopancreatic imaging systems (choledochoscopes) and related accessories; as well as non-vascular stents, retrieval devices and pulmonology products like airway stents. Founded in 2000 and headquartered in Nanjing, China, Micro-Tech operates globally with subsidiaries and sales channels in Europe (including Germany, the Netherlands, France, Switzerland and the UK), North America (USA), Japan, Thailand, Hong Kong and other regions across approximately 90 countries, serving hospitals and clinics with high-quality, innovative solutions to advance patient care and reduce costs. In May 2025, the company inaugurated a new 120,000-square-meter manufacturing campus in Nanjing Biotech and Pharmaceutical Valley, enhancing production capacity, product quality and global competitiveness through advanced facilities for manufacturing, warehousing and R&D. Micro-Tech recently completed the acquisition of a 51% stake in Creo Medical Europe (Creo Medical SLU) from Creo Medical Group plc in early 2025, bolstering its European presence, balance sheet with €30 million in proceeds for its partner and opening collaborative opportunities in medical device innovation. The company listed on the Shanghai Stock Exchange STAR Market in 2019 (ticker: 688029.SS) and maintains leadership in China as the largest producer of non-vascular stents and disposable biopsy forceps, holding over 50% domestic market share in key categories.